General information about company
Scrip code*		540204
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE666Q01016
Name of company		EIKO LIFESCIENCES LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2025
Date of end of financial year		31-03-2026
Date of board meeting when results were approved		29-01-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		16-01-2026
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Third quarter
Nature of report standalone or consolidated		Consolidated
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Unaudited
Segment Reporting		Multi segment
Description of single segment
Start date and time of board meeting		29-01-2026 12:30
End date and time of board meeting		29-01-2026 13:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	1198.36	3436.68
	Other income	31.71	84.34
	Total income	1230.07	3521.02
2	Expenses
(a)	Cost of materials consumed	900.92	2462.62
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	20.51	160.66
(d)	Employee benefit expense	19.57	45.86
(e)	Finance costs	6.68	21.47
(f)	Depreciation, depletion and amortisation expense	25.5	76.36
(g)	Other Expenses
1	Other expenses	69.77	252.34
	Total other expenses	69.77	252.34
	Total expenses	1042.95	3019.31
3	Total profit before exceptional items and tax	187.12	501.71
4	Exceptional items	0	0
5	Total profit before tax	187.12	501.71
6	Tax expense
7	Current tax	40.34	105.7
8	Deferred tax	7.33	21.44
9	Total tax expenses	47.67	127.14
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	139.45	374.57
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	3.09	8.19
16	Total profit (loss) for period	142.54	382.76
17	Other comprehensive income net of taxes	0	0
18	Total Comprehensive Income for the period	142.54	382.76
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	120.64	0
	Total profit or loss, attributable to non-controlling interests	21.91	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	120.64	319.62
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	21.91	63.13
21	Details of equity share capital
	Paid-up equity share capital	1372.09	1372.09
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.88	2.33
	Diluted earnings (loss) per share from continuing operations	0.88	2.33
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	0.88	2.33
	Diluted earnings (loss) per share from continuing and discontinued operations	0.88	2.33
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Specialty Chemicals & Pharma Intermediaries	1048.93	2914.39
2	Logistics Services	149.43	522.29
	Total Segment Revenue	1198.36	3436.68
	Less: Inter segment revenue	0	0
	Revenue from operations	1198.36	3436.68
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Specialty Chemicals & Pharma Intermediaries	81.49	198.06
2	Logistics Services	31.99	92.33
	Total Profit before tax	113.48	290.39
	i. Finance cost	6.68	21.47
	ii. Other Unallocable Expenditure net off Unallocable income	-83.42	-240.98
	Profit before tax	190.22	509.9
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Specialty Chemicals & Pharma Intermediaries	4076.44	4076.44
2	Logistics Services	1023.85	1023.85
	Total Segment Asset	5100.29	5100.29
	Un-allocable Assets	1808.68	1808.68
	Net Segment Asset	6908.97	6908.97
4	Segment Liabilities
	Segment Liabilities
1	Specialty Chemicals & Pharma Intermediaries	634.46	634.46
2	Logistics Services	191.13	191.13
	Total Segment Liabilities	825.59	825.59
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	825.59	825.59
	Disclosure of notes on segments

Other Comprehensive Income
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	0.00	0.00

General information about company

Financial Results – Ind-AS

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Other Comprehensive Income